
Aditya Birla SL Quant Fund Direct Growth Review 2026: NAV, Returns, Portfolio & Should You Invest?
Updated: 11 Sept 2026 • 3:14 pm
Posted by:

Aditya Birla SL Quant Fund Direct Growth Plan is an equity scheme with a current NAV of ₹10.48 as of 10 Sep 2026 and scheme AUM of ₹2,035 Cr. Its 1-year, 3-year and 5-year returns are 8.49%, 0% and 0%, and the fund sits in the High Risk category.
Our view is that this is a high-risk equity fund with a short live performance history, so it fits investors who can tolerate sharp swings and want to assess the strategy over a longer period. The benchmark behaviour has been mixed over the same windows, which makes the recent one-year gain more relevant than the unavailable longer-run figures.
Quick facts
| Particular | Details |
|---|---|
| NAV | ₹10.48 as of 10 Sep 2026 |
| AUM | ₹2,035 Cr |
| Expense Ratio | 0.62% |
| Launch Date | 28 Jun 2024 |
| Min SIP | ₹500 |
| Risk Category | High Risk |
| Benchmark | Nifty 50 |
| Fund Category | Equity |
| Exit Load | 0.50% on or before 90D, Nil after 90D |
| Fund Managers | Harish Krishnan, Kartikeya Singh |
The fund is managed by Harish Krishnan and Kartikeya Singh.
Source data date: as of 10 Sep 2026
Performance
| Period | Fund return | Benchmark return |
|---|---|---|
| 1M | -2.24% | -4.06% |
| 3M | 5.43% | 1.37% |
| 1Y | 8.49% | -7.31% |
| 3Y | Data not available | Data not available |
| 5Y | Data not available | Data not available |
The most recent month was soft, but the fund still held up better than the benchmark over that stretch. Over three months, the picture improved meaningfully, with the fund advancing while the benchmark was only modestly higher. That tells us the strategy has been able to recover after a weaker patch rather than follow a smooth line.
The one-year result is the main positive point: the fund is ahead of the benchmark by a wide margin over that period. At the same time, the live track record is still short, so we would treat the one-year outcome as an early indicator rather than a mature pattern.
The daily pattern over the year looks uneven, with several pullbacks and recoveries rather than a steady climb. That kind of behaviour is consistent with an equity strategy that may move sharply in both directions. For investors, the key question is not just whether returns are positive, but whether the path of returns is tolerable.
Because the scheme is young, the unavailable 3-year and 5-year figures limit what we can conclude about compounding. The current evidence suggests a fund that can outperform its benchmark in shorter windows, but one whose long-term profile still needs time to build.
Source data date: as of 10 Sep 2026
Should you BUY or HOLD Aditya Birla SL Quant?
A fund's past returns alone don't tell you whether you should buy it today or continue holding it.
The right decision depends on factors such as your current allocation, purchase price, risk profile, investment horizon and the role this fund plays in your overall portfolio.
Already holding Aditya Birla SL Quant? Thinking of investing now?
Peer comparison
| Fund | 1Y return | 3Y return | 5Y return |
|---|---|---|---|
| Aditya Birla SL Quant Fund Direct Growth Plan | 8.49% | Data not available | Data not available |
| ICICI Pru Strategic Metal and Energy Equity FoF Direct Growth Plan | 73.94% | 37.12% | Data not available |
| Motilal Oswal Active Momentum Fund Direct Growth Plan | 29.94% | Data not available | Data not available |
| Kotak Healthcare Fund Direct Growth Plan | 29.26% | Data not available | Data not available |
| HDFC Pharma and Healthcare Fund Direct Growth Plan | 28.3% | Data not available | Data not available |
| SBI Automotive Opportunities Fund Direct Growth Plan | 27.13% | Data not available | Data not available |
This assessment is prepared by Uniapps Investment Adviser Pvt. Ltd. under SEBI Registered Investment Adviser registration INA000017639. The current fund’s 1-year return is far below the strongest peer figures available in this set, even though it has outpaced the benchmark over the same period. The longer-horizon comparison is harder to judge because the current fund does not yet have 3-year or 5-year history, while most peer rows also lack those longer figures. As a result, the peer table points to a short-term gap in return strength, but it does not yet offer a clean long-term comparison.
Source data date: as of 10 Sep 2026
Want to know more? Log in to Univest for more mutual fund insights.
Portfolio: where your money goes
| Holding | Sector | Weight |
|---|---|---|
| Marico Ltd. | FMCG | 4.52% |
| Torrent Pharmaceuticals Ltd. | Healthcare | 4.38% |
| Nestle India Ltd. | FMCG | 4.29% |
| The Federal Bank Ltd. | Bank | 4.07% |
| Grasim Industries Ltd. | Diversified | 4.05% |
| Apollo Hospitals Enterprise Ltd. | Healthcare | 4.04% |
| State Bank of India | Bank | 3.58% |
| Laurus Labs Ltd. | Healthcare | 3.56% |
| Sun Pharmaceutical Industries Ltd. | Healthcare | 3.49% |
| Hindalco Industries Ltd. | Non – Ferrous Metals | 3.47% |
The top 10 holdings account for approximately 39.45% of the portfolio. To see all holdings, visit the Aditya Birla SL Quant Fund Direct Growth Plan page
Marico Ltd. is the largest disclosed holding at 4.52%, so no single position dominates the portfolio outright. The gap from the largest holding to the tenth holding is not extreme, moving from 4.52% to 3.47%, which suggests the disclosed book is fairly even across its leading positions.
That said, the top 10 still account for 39.45% of the portfolio, so the fund may remain influenced by a meaningful set of core ideas even though each one is sized in a similar range. With 39 disclosed holdings in total, the visible portfolio looks diversified enough to avoid very heavy concentration at the top, but the larger tail beyond the first 10 can still shape outcomes.
The mix across FMCG, healthcare, banking, diversified and metals names may give the portfolio a more balanced sector profile than a narrow thematic bet, but it still remains an equity strategy with High Risk characteristics. That means stock selection can matter more than broad market exposure, and the investment path may stay uneven in the short run.
Source data date: as of 10 Sep 2026
Who should invest
This fund suits investors who can tolerate a High Risk equity profile and are comfortable with short-term drawdowns. The one-year result is positive and ahead of the benchmark, but the live history is still short and the longer-return fields are not yet available, so the case for it depends more on conviction in the approach than on a full cycle record.
We think the fund is better viewed with a longer horizon, ideally one that allows time for the portfolio to show whether its recent recovery can continue. The main trade-off is that you may get faster upside in strong periods, but you also have to accept a bumpier path and the possibility that the pattern does not stay consistent.
Tax and exit load
| Holding period | Tax rate | Description |
|---|---|---|
| Units held less than 1 year | 20% | Short-term capital gains tax |
| Units held more than 1 year | 12.5% | Long-term capital gains tax |
Exit load: 0.50% on or before 90D, Nil after 90D.
Source data date: as of 10 Sep 2026
Frequently asked questions
What is the current NAV of Aditya Birla SL Quant Fund Direct Growth Plan?
The current NAV is ₹10.48 as of 10 Sep 2026.
What are the fund’s 1-year, 3-year and 5-year returns?
The 1-year return is 8.49%, while the 3-year and 5-year returns are not available yet.
How has the fund performed against Nifty 50?
It has done better than Nifty 50 over 1 year and 3 months, and also held up better over 1 month. The benchmark has been weaker over the 1-year window.
How does it compare with the peer funds listed here?
Its 1-year return is lower than the peer funds shown here, while the longer-term comparison is limited because the fund itself does not yet have 3-year or 5-year figures.
What is the minimum SIP amount?
The minimum SIP amount is ₹500.
What are the fund’s risk, portfolio and manager details?
It is a High Risk equity fund managed by Harish Krishnan and Kartikeya Singh. The top disclosed holdings are led by Marico Ltd., Torrent Pharmaceuticals Ltd. and Nestle India Ltd.
Bottom line
Aditya Birla SL Quant Fund Direct Growth Plan has shown a better short-term result than its benchmark, but its live history is still too short to judge the longer compounding pattern with confidence. The peer set also shows that its recent return is modest beside stronger short-term numbers elsewhere. The portfolio is reasonably spread across many holdings, with no single position overwhelmingly large, and the fund remains a High Risk equity option for investors who can handle uneven performance and want to watch the strategy over a longer horizon.
Published on 11 September 2026 at 3:13 PM IST
Explore mutual funds with Univest
Review mutual fund data, compare performance and explore fund insights on Univest.
RIA disclosure
Mutual fund investments are subject to market risks. Read all scheme-related documents carefully before investing. This review is prepared by Uniapps Investment Adviser Pvt. Ltd. (earlier known as Uniapps Global Research Pvt. Ltd.) under SEBI Registered Investment Adviser registration INA000017639 for general informational purposes and is not personalized investment advice.
Recent Articles

Motilal Oswal Quant Fund Direct Growth Review 2026: NAV, Returns, Portfolio & Should You Invest?
11 September 2026

HSBC Business Cycles Fund Direct Growth Review 2026: NAV, Returns, Portfolio & Should You Invest?
11 September 2026

Canara Rob Balanced Advantage Fund Direct Growth Review 2026: NAV, Returns, Portfolio & Should You Invest?
11 September 2026

HSBC Arbitrage Fund Direct Growth Review 2026: NAV, Returns, Portfolio & Should You Invest?
11 September 2026
Note: This blog is for information purpose only. Investments and trading are subject to market risks, read all scheme related documents carefully.
Reviews
Recent Posts
Motilal Oswal Quant Fund Direct Growth Review 2026: NAV, Returns, Portfolio & Should You Invest?
HSBC Business Cycles Fund Direct Growth Review 2026: NAV, Returns, Portfolio & Should You Invest?
Canara Rob Balanced Advantage Fund Direct Growth Review 2026: NAV, Returns, Portfolio & Should You Invest?
HSBC Arbitrage Fund Direct Growth Review 2026: NAV, Returns, Portfolio & Should You Invest?
Axis Credit Risk Fund Direct Growth Review 2026: NAV, Returns, Portfolio & Should You Invest?

Uniresearch Global Pvt Ltd
Research Analyst
SEBI Registration Number — INH000013776
Uniresearch is a subsidiary of Univest Communication Technologies Private Limited
Company Address: Registered Address: Ground Floor, Unitech Commercial Tower 2, Block B, Greenwood City, Unit 1-3, Sector 45, Gurugram, Haryana 122003
Write to us : support@univest.in, compliance@univest.in
Verify on SEBI registry →RESEARCH ANALYST
Get SEBI Registered
advice on the stocks
trending today.
Get 3 FREE Trade Ideas
for Startups Accelerator 2024
Trusted by 1Cr Indians
Awarded No.1 by Economic Times





